FDAnews Drug Daily Bulletin

INSULIN GAINS AT NOVO NORDISK

Nov. 14, 2005
A A

Novo Nordisk (NVO:NYSE ADR -- commentary -- research -- Cramer's Take) said it moved into a leadership position in the U.S. insulin market based on the most recent data on total insulin volume. The Danish diabetes-care company said the growth trend is centered around Novo Nordisk's flagship insulin products: NovoLog Mix 70/30 (70% insulin aspart protamine suspension and 30 percent insulin aspart injection) and NovoLog (insulin aspart injection). NovoLog Mix 70/30 FlexPen and NovoLog FlexPen are the leading insulin delivery devices in the U.S., Novo said.

The Street (http://www.thestreet.com/_googlen/stocks/healthcare/10252355.html?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA)